YEAR
- 2016.01.19 Identification of Novel HLA-A*24:02-Restricted Epitope Derived from a Homeobox Protein Expressed in Hematological Malignancies. Matsushita M, Otsuka Y, Tsutsumida N, Tanaka C, Uchiumi A, Ozawa K, Suzuki T, Ichikawa D, Aburatani H, Okamoto S, Kawakami Y, Hattori Y.PLoS ONE. 2016;11(1):e0146371. doi: 10.1371/journal.pone.0146371
- 2016.01.12 IER5 generates a novel hypo-phosphorylated active form of HSF1 and contributes to tumorigenesis. Asano Y, Kawase T, Okabe A, Tsutsumi S, Ichikawa H, Tatebe S, Kitabayashi I, Tashiro F, Namiki H, Kondo T, Semba K, Aburatani H, Taya Y, Nakagama H, Ohki R.Sci Rep. 2016 Jan 12;6:19174. doi: 10.1038/srep19174
- 2016.02.20 Integrated Multiregional Analysis Proposing a New Model of Colorectal Cancer Evolution. Uchi R, Takahashi Y, Niida A, Shimamura T, Hirata H, Sugimachi K, Sawada G, Iwaya T, Kurashige J, Shinden Y, Iguchi T, Eguchi H, Chiba K, Shiraishi Y, Nagae G, Yoshida K, Nagata Y, Haeno H, Yamamoto H, Ishii H, Doki Y, Iinuma H, et al.PLoS Genet. 2016 Feb 18;12(2):e1005778. doi: 10.1371/journal.pgen.1005778. eCollection 2016 Feb.
- 2016.09.09 Loss of YAP1 defines neuroendocrine differentiation of lung tumors. Ito T, Matsubara D, Tanaka I, Makiya K, Tanei ZI, Kumagai Y, Shiu SJ, Nakaoka HJ, Ishikawa S, Isagawa T, Morikawa T, Shinozaki-Ushiku A, Goto Y, Nakano T, Tsuchiya T, Tsubochi H, Komura D, Aburatani H, Dobashi Y, Nakajima J, Endo S, Fukayama M, Sekido Y, Niki T, Murakami Y.Cancer Sci. 2016 Oct;107(10):1527-1538. doi: 10.1111/cas.13013
- 2016.08.09 Lyn Kinase Suppresses the Transcriptional Activity of IRF5 in the TLR-MyD88 Pathway to Restrain the Development of Autoimmunity. Ban T, Sato GR, Nishiyama A, Akiyama A, Takasuna M, Umehara M, Suzuki S, Ichino M, Matsunaga S, Kimura A, Kimura Y, Yanai H, Miyashita S, Kuromitsu J, Tsukahara K, Yoshimatsu K, Endo I, Yamamoto T, Hirano H, Ryo A, Taniguchi T, Tamura T.Immunity. 2016 08 16;45(2):319-32. doi: 10.1016/j.immuni.2016.07.015
- 2016.11.15 MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53. Makii C, Oda K, Ikeda Y, Sone K, Hasegawa K, Uehara Y, Nishijima A, Asada K, Koso T, Fukuda T, Inaba K, Oki S, Machino H, Kojima M, Kashiyama T, Mori-Uchino M, Arimoto T, Wada-Hiraike O, Kawana K, Yano T, Fujiwara K, Aburatani H, Osuga Y, Fujii T.Oncotarget. 2016 Nov 15;7(46):75328-75338. doi: 10.18632/oncotarget.12175
- 2016.03.28 MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12/CXCR4 signaling and leukemogenesis. Yokoyama T, Nakatake M, Kuwata T, Couzinet A, Goitsuka R, Tsutsumi S, Aburatani H, Valk PJ, Delwel R, Nakamura T.J. Clin. Invest. 2016 05 02;126(5):1664-78. doi: 10.1172/JCI81516
- 2016.07.14 Molecular dynamics analysis to evaluate docking pose prediction. Sakano T, Mahamood MI, Yamashita T, Fujitani H.Biophys Physicobiol. 2016;13:181-194. doi: 10.2142/biophysico.13.0_181
CLOSE